Something old, something new and something very old: Drugs for treating type 2 diabetes

British Journal of Pharmacology

Volumn 171, Issue 12, 2014, Pages 2940-2950

  Kaiser, D ^a   Oetjen, Elke ^a,b,c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

anti diabetic drugs; beta cell function; inflammation; insulin resistance; type 2 diabetes mellitus

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; ALEGLITAZAR; DAPAGLIFLOZIN; ETANERCEPT; FASIGLIFAM; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLITAZAR DERIVATIVE; GLITAZONE DERIVATIVE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOKINASE; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INCB 13739; INTERLEUKIN 1BETA; METFORMIN; MK 0941; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIOGLITAZONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROSIGLITAZONE; SALICYLIC ACID; SALSALATE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

DRUG MECHANISM; DRUG TARGETING; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN RELEASE; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; WEIGHT GAIN; ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECTS; METABOLISM; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; SALICYLIC ACID; TREATMENT OUTCOME;

EID: 84901466134     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12624     Document Type: Review

References (130)

1. Aguirre V, Uchida T, Yenush L, Davis R, White MF, (2000). The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 275: 9047-9054.
2. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, et al. (2013). PPARγ signaling and metabolism: the good, the bad and the future. Nat Med 19: 557-566.
3. Alberti KG, Zimmet PZ, (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Ion Channels. Br J Pharmacol 170: 1607-1651.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
6. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Transporters. Br J Pharmacol 170: 1706-1796.
7. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013d). The Concise Guide to PHARMACOLOGY 2013/14: Nuclear Hormone Receptors. Br J Pharmacol 170: 1652-1675.
8. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013e). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581
9. American Diabetes Association (2004). Diagnosis and classification of diabetes mellitus. Diabetes Care 27 (Suppl. 1): S5-S10.
10. Anagnostis P, Katsiki N, Adamidou F, Athyros VG, Karagiannis A, Kita M, et al. (2013). 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? Metabolism 62: 21-33.
11. Bhalla K, Hwang BJ, Choi JH, Dewi R, Ou L, McLenithan J, et al. (2011). N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor gamma ligand with partial and full agonist activity in vitro and in vivo. J Biol Chem 286: 41626-41635.
12. Boon H, Bosselaar M, Praet SFE, Blaak EE, Saris WHM, Wagenmakers AJM, et al. (2008). Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients. Diabetologia 51: 1893-1900.
13. Brooks-Worrell B, Narla R, Palmer JP, (2012). Biomarkers and immune-modulating therapies for type 2 diabetes. Trends Immunol 33: 546-553.
14. Burant CF, Viswanathan P, Marcinak J, Cao C, Vakilynejad M, Xie B, et al. (2012). TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379 (9824): 1403-1411.
15. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC, (2003). Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52: 102-110.
16. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC, (2013a). Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 62: 2595-2604.
17. Butler PC, Elashoff M, Elashoff R, Gale EA, (2013b). A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 36: 2118-2125.
18. Cheon HG, (2013). Latest research and development trends in non-insulin anti-diabetics. Arch Pharm Res 36: 145-153.
19. Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, Kumar N, et al. (2011). Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 477 (7365): 477-481.
20. Conarello SL, Jiang G, Mu J, Li Z, Woods J, Zycband E, et al. (2007). Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia 50: 142-150.
21. Cronstein BN, Montesinos MC, Weissmann G, (1999). Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB. Proc Natl Acad Sci U S A 96: 6377-6381.
22. D'Alessio D, (2011). The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes Metab 13 (Suppl. 1): 126-132.
23. De Ceuninck F, Kargar C, Charton Y, Goldstein S, Perron-Sierra F, Ilic C, et al. (2013). S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice. Br J Pharmacol 169: 999-1010.
24. Donath MY, Shoelson SE, (2011). Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11: 98-107.
25. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. (2005). Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279-1289.
26. Doyle ME, Egan JM, (2001). Glucagon-like peptide-1. Recent Prog Horm Res 56: 377-399.
27. Ebstein W, (1876). Zur therapie des diabetes mellitus, insbesondere uber die anwendung des salicylsauren natron bei demselben. Berl Klin Wochenschr 13: 337-340.
28. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD, (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ 330 (7503): 1304-1305.
29. Faghihimani E, Aminorroaya A, Rezvanian H, Adibi P, Ismail-Beigi F, Amini M, (2013). Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes. Acta Diabetol 50: 537-543.
30. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, et al. (2010). Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 120: 2355-2369.
31. Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, et al. (2012). 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 380: 475-483.
32. Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, Cui L, et al. (2003). Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 100: 1438-1443.
33. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC, (2012). Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes 61: 1250-1262.
34. Giorgino F, Leonardini A, Laviola L, (2013). Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. Ann N Y Acad Sci 1281: 36-50.
35. Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE, (2010). The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 152: 346-357.
36. Goldfine AB, Conlin PR, Halperin F, Koska J, Permana P, Schwenke D, et al. (2013a). A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia 56: 714-723.
37. Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA, et al. (2013b). Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med 159: 1-12.
38. Gonzalez M, Boer U, Dickel C, Quentin T, Cierny I, Oetjen E, et al. (2008). Loss of insulin-induced inhibition of glucagon gene transcription in hamster pancreatic islet alpha cells by long-term insulin exposure. Diabetologia 51: 2012-2021.
39. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, et al. (2011). Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50: 81-98.
40. Gromada J, Franklin I, Wollheim CB, (2007). α-Cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28: 84-116.
41. UKPDS Group (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 837-853.
42. Grzeskowiak R, Amin J, Oetjen E, Knepel W, (2000). Insulin responsiveness of the glucagon gene conferred by interactions between proximal promoter and more distal enhancer-like elements involving the paired-domain transcription factor Pax6. J Biol Chem 275: 30037-30045.
43. Hardie DG, (2013). AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes 62: 2164-2172.
44. Hardie DG, Ross FA, Hawley SA, (2012). AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13: 251-262.
45. Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, et al. (2012). The ancient drug salicylate directly activates AMP-activated protein kinase. Science 336: 918-922.
46. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M, (2009). Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 374: 126-135.
47. Higgs GA, Moncada S, Vane JR, (1984). Eicosanoids in inflammation. Ann Clin Res 16: 287-299.
48. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, et al. (2002). A central role for JNK in obesity and insulin resistance. Nature 420 (6913): 333-336.
49. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. (2009). Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373 (9681): 2125-2135.
50. Hotamisligil GS, Shargill NS, Spiegelman BM, (1993). Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 (5091): 87-91.
51. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM, (1995). Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95: 2409-2415.
52. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. (2000). Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595-1599.
53. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, et al. (2002). Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109: 1321-1326.
54. Kahn SE, Zraika S, Utzschneider KM, Hull RL, (2009). The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. Diabetologia 52: 1003-1012.
55. Kaul S, Diamond GA, (2011). Is there clear and convincing evidence of cardiovascular risk with rosiglitazone? Clin Pharmacol Ther 89: 773-776.
56. Kawamori D, Kurpad AJ, Hu J, Liew CW, Shih JL, Ford EL, et al. (2009). Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metab 9: 350-361.
57. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403.
58. Koo SH, Flechner L, Qi L, Zhang X, Screaton RA, Jeffries S, et al. (2005). The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437 (7062): 1109-1111.
59. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, et al. (2007). Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356: 1517-1526.
60. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T, (2009). Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32: 1663-1668.
61. Lavery GG, Zielinska AE, Gathercole LL, Hughes B, Semjonous N, Guest P, et al. (2012). Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11β-hydroxysteroid dehydrogenase type 1. Endocrinology 153: 3236-3248.
62. Lazar MA, (2005). How obesity causes diabetes: not a tall tale. Science 307: 373-375.
63. Liang Y, Osborne MC, Monia BP, Bhanot S, Gaarde WA, Reed C, et al. (2004). Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 53: 410-417.
64. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM, (2009). New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32: 1620-1625.
65. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE, (2007). Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298: 1180-1188.
66. Logie L, Harthill J, Patel K, Bacon S, Hamilton DL, Macrae K, et al. (2012). Cellular responses to the metal-binding properties of metformin. Diabetes 61: 1423-1433.
67. Lumeng CN, Saltiel AR, (2011). Inflammatory links between obesity and metabolic disease. J Clin Invest 121: 2111-2117.
68. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, et al. (2002). Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110: 851-860.
69. Marchetti P, Bugliani M, Boggi U, Masini M, Marselli L, (2012). The pancreatic beta cells in human type 2 diabetes. Adv Exp Med Biol 771: 288-309.
70. Martin-Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL, Scheibye-Knudsen M, et al. (2013). Metformin improves healthspan and lifespan in mice. Nat Commun 4: 2192.
71. Matschinsky FM, (2013). GKAs for diabetes therapy: why no clinically useful drug after two decades of trying? Trends Pharmacol Sci 34: 90-99.
72. Matschinsky FM, Zelent B, Doliba NM, Kaestner KH, Vanderkooi JM, Grimsby J, et al. (2011). Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects. Handb Exp Pharmacol 203: 357-401.
73. Meininger GE, Scott R, Alba M, Shentu Y, Luo E, Amin H, et al. (2011). Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 34: 2560-2566.
74. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ, (2013). Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 494 (7436): 256-260.
75. Monami M, Luzzi C, Lamanna C, Chiasserini V, Addante F, Desideri CM, et al. (2006). Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 22: 477-482.
76. Monami M, Balzi D, Lamanna C, Barchielli A, Masotti G, Buiatti E, et al. (2007). Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 23: 479-484.
77. Morgan SA, Sherlock M, Gathercole LL, Lavery GG, Lenaghan C, Bujalska IJ, et al. (2009). 11beta-Hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes 58: 2506-2515.
78. Nachnani JS, Bulchandani DG, Nookala A, Herndon B, Molteni A, Pandya P, et al. (2010). Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 53: 153-159.
79. Nauck MA, (2013). A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care 36: 2126-2132.
80. Nissen SE, Wolski K, (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471.
81. Nissen SE, Wolski K, (2010). Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 170: 1191-1201.
82. Nixon M, Wake DJ, Livingstone DE, Stimson RH, Esteves CL, Seckl JR, et al. (2012). Salicylate downregulates 11β-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization. Diabetes 61: 790-796.
83. Noto H, Goto A, Tsujimoto T, Noda M, (2012). Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE 7: e33411.
84. Odegaard JI, Chawla A, (2013). Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 339 (6116): 172-177.
85. Oetjen E, Blume R, Cierny I, Schlag C, Kutschenko A, Kratzner R, et al. (2007). Inhibition of MafA transcriptional activity and human insulin gene transcription by interleukin-1beta and mitogen-activated protein kinase kinase kinase in pancreatic islet beta cells. Diabetologia 50: 1678-1687.
86. Osbak KK, Colclough K, Saint-Martin C, Beer NL, Bellanne-Chantelot C, Ellard S, et al. (2009). Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 30: 1512-1526.
87. Pabreja K, Mohd MA, Koole C, Wootten D, Furness SG, (2014). Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation. Br J Pharmacol 171: 1114-1128.
88. Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S, et al. (2012). Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 18.
89. Philippe J, (1989). Glucagon gene transcription is negatively regulated by insulin in a hamster islet cell line. J Clin Invest 84: 672-677.
90. Plomgaard P, Nielsen AR, Fischer CP, Mortensen OH, Broholm C, Penkowa M, et al. (2007). Associations between insulin resistance and TNF-alpha in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes. Diabetologia 50: 2562-2571.
91. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB, (1987). Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64: 106-110.
92. Rees MG, Gloyn AL, (2013). Small molecular glucokinase activators: has another new anti-diabetic therapeutic lost favour? Br J Pharmacol 168: 335-338.
93. Rena G, Pearson ER, Sakamoto K, (2013). Molecular mechanism of action of metformin: old or new insights? Diabetologia 56: 1898-1906.
94. Rhodes CJ, (2005). Type 2 diabetes-a matter of beta-cell life and death? Science 307 (5708): 380-384.
95. Rosenson RS, Wright RS, Farkouh M, Plutzky J, (2012). Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. Am Heart J 164: 672-680.
96. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE, (2010). Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev (4): CD002967.
97. Saltiel AR, (2012). Insulin resistance in the defense against obesity. Cell Metab 15: 798-804.
98. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. (2013). Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369: 1317-1326.
99. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, et al. (2005). The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310 (5754): 1642-1646.
100. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, et al. (2007). Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117: 1422-1431.
101. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB, (2013). Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 173: 534-539.
102. Skoglund G, Hussain MA, Holz GG, (2000). Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element. Diabetes 49: 1156-1164.
103. Sonoda N, Imamura T, Yoshizaki T, Babendure JL, Lu JC, Olefsky JM, (2008). Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells. Proc Natl Acad Sci U S A 105: 6614-6619.
104. Sorensen H, Brand CL, Neschen S, Holst JJ, Fosgerau K, Nishimura E, et al. (2006a). Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes 55: 2843-2848.
105. Sorensen H, Winzell MS, Brand CL, Fosgerau K, Gelling RW, Nishimura E, et al. (2006b). Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function. Diabetes 55: 3463-3469.
106. van Staa TP, Patel D, Gallagher AM, de Bruin ML, (2012). Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 55: 654-665.
107. Stanley TL, Zanni MV, Johnsen S, Rasheed S, Makimura H, Lee H, et al. (2011). TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab 96: E146-E150.
108. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, et al. (2000). Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49: 741-748.
109. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (7258): 405-412.
110. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH, (2011). Management of type 2 diabetes: new and future developments in treatment. Lancet 378 (9786): 182-197.
111. Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T, et al. (1994). Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372 (6502): 182-186.
112. Thisted H, Johnsen SP, Rungby J, (2006). Sulfonylureas and the risk of myocardial infarction. Metabolism 55 (Suppl. 1): S16-S19.
113. Thornberry NA, Gallwitz B, (2009). Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab 23: 479-486.
114. Tremaroli V, Backhed F, (2012). Functional interactions between the gut microbiota and host metabolism. Nature 489 (7415): 242-249.
115. Ueki K, Kondo T, Kahn CR, (2004). Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24: 5434-5446.
116. Unger RH, (1985). Glucagon physiology and pathophysiology in the light of new advances. Diabetologia 28: 574-578.
117. Unger RH, Cherrington AD, (2012). Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 122: 4-12.
118. Viollet B, Foretz M, (2013). Revisiting the mechanisms of metformin action in the liver. Ann Endocrinol (Paris) 74: 123-129.
119. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F, (2012). Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 122: 253-270.
120. Weidner C, de Groot JC, Prasad A, Freiwald A, Quedenau C, Kliem M, et al. (2012). Amorfrutins are potent antidiabetic dietary natural products. Proc Natl Acad Sci U S A 109: 7257-7262.
121. Weidner C, Wowro SJ, Freiwald A, Kawamoto K, Witzke A, Kliem M, et al. (2013). Amorfrutin B is an efficient natural peroxisome proliferator-activated receptor gamma (PPARγ) agonist with potent glucose-lowering properties. Diabetologia 56: 1802-1812.
122. Weir GC, Bonner-Weir S, (2013). Islet beta cell mass in diabetes and how it relates to function, birth, and death. Ann N Y Acad Sci 1281: 92-105.
123. Werner ED, Lee J, Hansen L, Yuan M, Shoelson SE, (2004). Insulin resistance due to phosphorylation of insulin receptor substrate-1 at serine 302. J Biol Chem 279: 35298-35305.
124. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. (2013). Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369: 1327-1335.
125. Wilding JPH, (2012). PPAR agonists for the treatment of cardiovascular disease in patients with diabetes. Diabetes Obes Metab 14: 973-982.
126. Winterstein AG, (2011). Rosiglitazone and the risk of adverse cardiovascular outcomes. Clin Pharmacol Ther 89: 776-778.
127. Xu G, Stoffers DA, Habener JF, Bonner-Weir S, (1999). Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48: 2270-2276.
128. Yashiro H, Tsujihata Y, Takeuchi K, Hazama M, Johnson PR, Rorsman P, (2012). The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. J Pharmacol Exp Ther 340: 483-489.
129. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, et al. (2001). Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293 (5535): 1673-1677.
130. Zhu Z, Shen Z, Lu Y, Zhong S, Xu C, (2012). Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 98: 159-163.